{"id":848224,"date":"2025-05-07T09:07:50","date_gmt":"2025-05-07T13:07:50","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/moleculin-to-report-first-quarter-2025-financial-results-on-may-13-2025-and-host-conference-call-and-webcast\/"},"modified":"2025-05-07T09:07:50","modified_gmt":"2025-05-07T13:07:50","slug":"moleculin-to-report-first-quarter-2025-financial-results-on-may-13-2025-and-host-conference-call-and-webcast","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/moleculin-to-report-first-quarter-2025-financial-results-on-may-13-2025-and-host-conference-call-and-webcast\/","title":{"rendered":"Moleculin to Report First Quarter 2025 Financial Results on May 13, 2025 and Host Conference Call and Webcast"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">\n        <strong>HOUSTON, May  07, 2025  (GLOBE NEWSWIRE) &#8212; Moleculin Biotech, Inc.<\/strong>, (Nasdaq: MBRX) (\u201cMoleculin\u201d or the \u201cCompany\u201d), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat cancers and viruses, today announced that it will report its financial results for the first quarter ended March 31, 2025 on Tuesday afternoon, May 13, 2025. Moleculin management will host a conference call and <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=XsqwwwxPjQsY59t3n-NJXj7R5GyeC0PrkuuGBIrW62SRnUUgZpGdzvdj7G4draD09Yf1BwhrkzZvCYcfw0a14YZ5f_sweIxjOdVC4mgB3doMYZcWeyDj-32fnyuGIlZNgPTnp4wANkP-RcwkitVYyOwMMCeYXyG0jZX3SH5C-GQ=\" rel=\"nofollow\" target=\"_blank\">live audio webcast<\/a> to discuss the operational and financial results on Wednesday morning, May 14, 2025 at 8:30 AM ET.<\/p>\n<p align=\"justify\">Interested participants and investors may access the conference call by dialing (877) 407-0832 (domestic) or (201) 689-8433 (international) and referencing the Moleculin Biotech Conference Call. The\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=XsqwwwxPjQsY59t3n-NJXh4wmEazD_JkTzXI0rJc-Sg3a2Dr85Y2BKyNY3G3eyz8RtGzYHFhRIKt5MY506shUe23xCdISoZ1dbQe7sW8gPq1ObUSUyBq-vZL2LfOdWnjaxbzmLJf_0CtFB-ET-4eGpRrsqysxFw_kJ2Pj0aGJ84=\" rel=\"nofollow\" target=\"_blank\">live audio webcast\u00a0<\/a>will be accessible on the\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=FAtXkpRj4mwnqV4oU3UmFCKGf5pRrkIM9VH-ce_9uzgG7Z_7Nm9foe5s_FSCw2CvUoF_RznkF42blt_31Dsoqg==\" rel=\"nofollow\" target=\"_blank\">Events<\/a>\u00a0page of the\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=kaENLW4jI3WKRT7BPr3CF7wlnylasa7HQ9P6GGFaF528al314TphNvvCRMvWPbmgGbNPdVSIF3I5squB5CGDJLxFm90HEQhhe6bPu9twMjQ=\" rel=\"nofollow\" target=\"_blank\">Investors<\/a>\u00a0section of the Moleculin website,\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Pchc8aAIbZulpXqObKd6lvWPrqg9fVxzT5Wj5VQBbZJgkgYTOGPscUlXeHmOOwVv33DMYOKwSk2GZV8rP8yD7Q==\" rel=\"nofollow\" target=\"_blank\">moleculin.com<\/a>, and will be archived for 90 days.<\/p>\n<p>\n        <strong>About Moleculin Biotech, Inc.<\/strong>\n      <\/p>\n<p align=\"justify\">Moleculin Biotech, Inc. is a Phase 3 clinical stage pharmaceutical company advancing a pipeline of therapeutic candidates addressing hard-to-treat tumors and viruses. The Company\u2019s lead program, Annamycin, is a next-generation highly efficacious and well tolerated anthracycline designed to avoid multidrug resistance mechanisms and to eliminate the cardiotoxicity common with currently prescribed anthracyclines. Annamycin is currently in development for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma (STS) lung metastases.<\/p>\n<p>In March of this year, the Company initiated recruitment of patients into its MIRACLE (<strong>M<\/strong>olecul<strong>i<\/strong>n <strong>R<\/strong>\/R AML <strong>A<\/strong>nnAraC <strong>Cl<\/strong>inical <strong>E<\/strong>valuation) Trial (MB-108), a pivotal, adaptive design Phase 3 trial evaluating Annamycin in combination with cytarabine, together referred to as AnnAraC, for the treatment of relapsed or refractory acute myeloid leukemia. Following a successful Phase 1B\/2 study (MB-106), with input from the FDA, the Company believes it has substantially de-risked the development pathway towards a potential approval for Annamycin for the treatment of AML. This study is subject to appropriate future filings with potential additional feedback from the FDA and their foreign equivalents.<\/p>\n<p>Additionally, the Company is developing WP1066, an Immune\/Transcription Modulator capable of inhibiting p-STAT3 and other oncogenic transcription factors while also stimulating a natural immune response, targeting brain tumors, pancreatic and other cancers. Moleculin is also engaged in the development of a portfolio of antimetabolites, including WP1122 for the potential treatment of pathogenic viruses, as well as certain cancer indications.<\/p>\n<p align=\"justify\">For more information about the Company, please visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=9m8mx_vpMfMSoFZ31i-ZW_K-ZhAVkCCuc1LnPgMx3e3A9S-O4QxLd_ME0NMnN9SSbt4T6g_3HyUuk7UVlfZ7ZxFhYZvlekk0IgHEy1B0_yA=\" rel=\"nofollow\" target=\"_blank\">www.moleculin.com<\/a> and connect on <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Si6YwthlsPLGdyRTahHGdip5uGKmWkCtjwrB1Tp0utdjJMdmbM27wRZP0XH0akoiOkDB_fkRk9wd2wey4_uEUA==\" rel=\"nofollow\" target=\"_blank\">X<\/a>, <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=QFy9ODpJ0kEqH5eaANHAoWgsTTqk0Snzx50L0xa7nIM7qLmzYCrKAl9tN53DQBdcduRrW7Vw7JMHvJ1cxi77gEWdO3pqakHwvN1suO6171PzlR6jqi8bnxwKCQSg3N9m\" rel=\"nofollow\" target=\"_blank\">LinkedIn<\/a> and <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=5Vpl5mqjYlP3XjqpX9cRMZHSY7RrSHOFDJydOZmAsTx7FY6DkCxnimDVp8WfQdSDxcTl_Q4l57jtGM3L2GeADK6FAf-mmVbFmTqJAB31svk=\" rel=\"nofollow\" target=\"_blank\">Facebook<\/a>.<\/p>\n<p align=\"justify\">\n        <strong>Forward-Looking Statements<\/strong><\/p>\n<p>Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Forward-looking statements in this press release include, without limitation, the timing of the initial data readout in the MIRACLE trial. Moleculin will require significant additional financing, for which the Company has no commitments, in order to conduct its clinical trials as described in this press release, and the milestones described in this press release assume the Company\u2019s ability to secure such financing on a timely basis. Although Moleculin believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. Moleculin has attempted to identify forward-looking statements by terminology including \u2018believes,\u2019 \u2018estimates,\u2019 \u2018anticipates,\u2019 \u2018expects,\u2019 \u2018plans,\u2019 \u2018projects,\u2019 \u2018intends,\u2019 \u2018potential,\u2019 \u2018may,\u2019 \u2018could,\u2019 \u2018might,\u2019 \u2018will,\u2019 \u2018should,\u2019 \u2018approximately\u2019 or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, including those discussed under Item 1A. \u201cRisk Factors\u201d in our most recently filed Form 10-K filed with the Securities and Exchange Commission (SEC) and updated from time to time in our Form 10-Q filings and in our other public filings with the SEC. Any forward-looking statements contained in this release speak only as of its date. We undertake no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.<\/p>\n<p>\n        <strong>Investor Contact:<\/strong><br \/>\n        <br \/>JTC Team, LLC<br \/>Jenene Thomas<br \/>(908) 824-0775<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=S6CvyGHbER7g4cwZ5e1kP5eBV7TwJ6VnuDvFtXx0q-mFU6IBrXr1t-BcREj9hs7vB1qJRpAH6C4HpCYuxBqeKg==\" rel=\"nofollow\" target=\"_blank\">MBRX@jtcir.com<\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ0NjAyMCM2OTI1NTMwIzUwMDEzMzYwNw==\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/MjBmZDgwMDYtZGY5MC00MDkyLThkZjEtNjNkMDE1MjIxNDVlLTUwMDEzMzYwNy0yMDI1LTA1LTA3LWVu\/tiny\/Moleculin-Biotech-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>HOUSTON, May 07, 2025 (GLOBE NEWSWIRE) &#8212; Moleculin Biotech, Inc., (Nasdaq: MBRX) (\u201cMoleculin\u201d or the \u201cCompany\u201d), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat cancers and viruses, today announced that it will report its financial results for the first quarter ended March 31, 2025 on Tuesday afternoon, May 13, 2025. Moleculin management will host a conference call and live audio webcast to discuss the operational and financial results on Wednesday morning, May 14, 2025 at 8:30 AM ET. Interested participants and investors may access the conference call by dialing (877) 407-0832 (domestic) or (201) 689-8433 (international) and referencing the Moleculin Biotech Conference Call. The\u00a0live audio webcast\u00a0will be accessible on the\u00a0Events\u00a0page of the\u00a0Investors\u00a0section of the Moleculin &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/moleculin-to-report-first-quarter-2025-financial-results-on-may-13-2025-and-host-conference-call-and-webcast\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Moleculin to Report First Quarter 2025 Financial Results on May 13, 2025 and Host Conference Call and Webcast&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-848224","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.1 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Moleculin to Report First Quarter 2025 Financial Results on May 13, 2025 and Host Conference Call and Webcast - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/moleculin-to-report-first-quarter-2025-financial-results-on-may-13-2025-and-host-conference-call-and-webcast\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Moleculin to Report First Quarter 2025 Financial Results on May 13, 2025 and Host Conference Call and Webcast - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"HOUSTON, May 07, 2025 (GLOBE NEWSWIRE) &#8212; Moleculin Biotech, Inc., (Nasdaq: MBRX) (\u201cMoleculin\u201d or the \u201cCompany\u201d), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat cancers and viruses, today announced that it will report its financial results for the first quarter ended March 31, 2025 on Tuesday afternoon, May 13, 2025. Moleculin management will host a conference call and live audio webcast to discuss the operational and financial results on Wednesday morning, May 14, 2025 at 8:30 AM ET. Interested participants and investors may access the conference call by dialing (877) 407-0832 (domestic) or (201) 689-8433 (international) and referencing the Moleculin Biotech Conference Call. The\u00a0live audio webcast\u00a0will be accessible on the\u00a0Events\u00a0page of the\u00a0Investors\u00a0section of the Moleculin &hellip; Continue reading &quot;Moleculin to Report First Quarter 2025 Financial Results on May 13, 2025 and Host Conference Call and Webcast&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/moleculin-to-report-first-quarter-2025-financial-results-on-may-13-2025-and-host-conference-call-and-webcast\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-05-07T13:07:50+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ0NjAyMCM2OTI1NTMwIzUwMDEzMzYwNw==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/moleculin-to-report-first-quarter-2025-financial-results-on-may-13-2025-and-host-conference-call-and-webcast\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/moleculin-to-report-first-quarter-2025-financial-results-on-may-13-2025-and-host-conference-call-and-webcast\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Moleculin to Report First Quarter 2025 Financial Results on May 13, 2025 and Host Conference Call and Webcast\",\"datePublished\":\"2025-05-07T13:07:50+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/moleculin-to-report-first-quarter-2025-financial-results-on-may-13-2025-and-host-conference-call-and-webcast\\\/\"},\"wordCount\":696,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/moleculin-to-report-first-quarter-2025-financial-results-on-may-13-2025-and-host-conference-call-and-webcast\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQ0NjAyMCM2OTI1NTMwIzUwMDEzMzYwNw==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/moleculin-to-report-first-quarter-2025-financial-results-on-may-13-2025-and-host-conference-call-and-webcast\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/moleculin-to-report-first-quarter-2025-financial-results-on-may-13-2025-and-host-conference-call-and-webcast\\\/\",\"name\":\"Moleculin to Report First Quarter 2025 Financial Results on May 13, 2025 and Host Conference Call and Webcast - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/moleculin-to-report-first-quarter-2025-financial-results-on-may-13-2025-and-host-conference-call-and-webcast\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/moleculin-to-report-first-quarter-2025-financial-results-on-may-13-2025-and-host-conference-call-and-webcast\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQ0NjAyMCM2OTI1NTMwIzUwMDEzMzYwNw==\",\"datePublished\":\"2025-05-07T13:07:50+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/moleculin-to-report-first-quarter-2025-financial-results-on-may-13-2025-and-host-conference-call-and-webcast\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/moleculin-to-report-first-quarter-2025-financial-results-on-may-13-2025-and-host-conference-call-and-webcast\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/moleculin-to-report-first-quarter-2025-financial-results-on-may-13-2025-and-host-conference-call-and-webcast\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQ0NjAyMCM2OTI1NTMwIzUwMDEzMzYwNw==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQ0NjAyMCM2OTI1NTMwIzUwMDEzMzYwNw==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/moleculin-to-report-first-quarter-2025-financial-results-on-may-13-2025-and-host-conference-call-and-webcast\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Moleculin to Report First Quarter 2025 Financial Results on May 13, 2025 and Host Conference Call and Webcast\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Moleculin to Report First Quarter 2025 Financial Results on May 13, 2025 and Host Conference Call and Webcast - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/moleculin-to-report-first-quarter-2025-financial-results-on-may-13-2025-and-host-conference-call-and-webcast\/","og_locale":"en_US","og_type":"article","og_title":"Moleculin to Report First Quarter 2025 Financial Results on May 13, 2025 and Host Conference Call and Webcast - Market Newsdesk","og_description":"HOUSTON, May 07, 2025 (GLOBE NEWSWIRE) &#8212; Moleculin Biotech, Inc., (Nasdaq: MBRX) (\u201cMoleculin\u201d or the \u201cCompany\u201d), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat cancers and viruses, today announced that it will report its financial results for the first quarter ended March 31, 2025 on Tuesday afternoon, May 13, 2025. Moleculin management will host a conference call and live audio webcast to discuss the operational and financial results on Wednesday morning, May 14, 2025 at 8:30 AM ET. Interested participants and investors may access the conference call by dialing (877) 407-0832 (domestic) or (201) 689-8433 (international) and referencing the Moleculin Biotech Conference Call. The\u00a0live audio webcast\u00a0will be accessible on the\u00a0Events\u00a0page of the\u00a0Investors\u00a0section of the Moleculin &hellip; Continue reading \"Moleculin to Report First Quarter 2025 Financial Results on May 13, 2025 and Host Conference Call and Webcast\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/moleculin-to-report-first-quarter-2025-financial-results-on-may-13-2025-and-host-conference-call-and-webcast\/","og_site_name":"Market Newsdesk","article_published_time":"2025-05-07T13:07:50+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ0NjAyMCM2OTI1NTMwIzUwMDEzMzYwNw==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/moleculin-to-report-first-quarter-2025-financial-results-on-may-13-2025-and-host-conference-call-and-webcast\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/moleculin-to-report-first-quarter-2025-financial-results-on-may-13-2025-and-host-conference-call-and-webcast\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Moleculin to Report First Quarter 2025 Financial Results on May 13, 2025 and Host Conference Call and Webcast","datePublished":"2025-05-07T13:07:50+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/moleculin-to-report-first-quarter-2025-financial-results-on-may-13-2025-and-host-conference-call-and-webcast\/"},"wordCount":696,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/moleculin-to-report-first-quarter-2025-financial-results-on-may-13-2025-and-host-conference-call-and-webcast\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ0NjAyMCM2OTI1NTMwIzUwMDEzMzYwNw==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/moleculin-to-report-first-quarter-2025-financial-results-on-may-13-2025-and-host-conference-call-and-webcast\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/moleculin-to-report-first-quarter-2025-financial-results-on-may-13-2025-and-host-conference-call-and-webcast\/","name":"Moleculin to Report First Quarter 2025 Financial Results on May 13, 2025 and Host Conference Call and Webcast - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/moleculin-to-report-first-quarter-2025-financial-results-on-may-13-2025-and-host-conference-call-and-webcast\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/moleculin-to-report-first-quarter-2025-financial-results-on-may-13-2025-and-host-conference-call-and-webcast\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ0NjAyMCM2OTI1NTMwIzUwMDEzMzYwNw==","datePublished":"2025-05-07T13:07:50+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/moleculin-to-report-first-quarter-2025-financial-results-on-may-13-2025-and-host-conference-call-and-webcast\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/moleculin-to-report-first-quarter-2025-financial-results-on-may-13-2025-and-host-conference-call-and-webcast\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/moleculin-to-report-first-quarter-2025-financial-results-on-may-13-2025-and-host-conference-call-and-webcast\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ0NjAyMCM2OTI1NTMwIzUwMDEzMzYwNw==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ0NjAyMCM2OTI1NTMwIzUwMDEzMzYwNw=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/moleculin-to-report-first-quarter-2025-financial-results-on-may-13-2025-and-host-conference-call-and-webcast\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Moleculin to Report First Quarter 2025 Financial Results on May 13, 2025 and Host Conference Call and Webcast"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/848224","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=848224"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/848224\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=848224"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=848224"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=848224"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}